Clinical Trials > Beyond First Line Therapy
It is not the intention of the Cholangiocarcinoma Foundation to provide specific medical advice. We provide website users with information to help them better understand their health conditions and the current approaches related to prevention, diagnosis, treatment and supportive care. You are urged to always seek the advice of your physician or other qualified healthcare provider.
This is a multicenter, open-label, uncontrolled, repeat-dose phase 1/2a study designed to evaluate the safety profile and to determine the Recommended Dose of GNS561 in patients with advanced advanced primary liver cancer (Hepatocarcinoma, Intrahepatic Cholangiocarcinoma). This study consists of 2 parts: escalation and expansion phase.Read More
This is a phase II study of the combination of 2 immunotherapy drugs (durvalumab and tremelimumab) with radiation therapy in patients with hepatocellular carcinoma (HCC) with an exploratory cohort of patients with metastatic biliary tract cancer (BTC).Read More
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 and to further evaluate its safety, tolerability, and efficacy in expansion cohorts once the MTD is determined.Read More
The goal his clinical research study is to learn if the study drug ABC294640 can help to control advanced, unresectable intra-hepatic, perihilar or extra-hepatic cholangiocarcinoma (CCA). The safety of this drug will also be studied.Read More
This is a trial of combining a HDAC inhibitor and a PD1 inhibitor (immunotherapy drug) to make cholangiocarcinoma more sensitive to immunotherapy. This is based on laboratory data that shows HDAC inhibitors can make tumors more sensitive to immunotherapy.Read More
This Phase II clinical trial will establish the effectiveness of BGJ398 in patients harboring the FGFR2 gene fusion/translocation, which are errors in the DNA. Adult patients with histologically or cytologically confirmed (tumor biopsy), advanced or metastatic cholangiocarcinoma harboring the FGFR2 gene fusion/ translocation are eligible for enrollment. Phase II clinical trials give doctors more information about the safety of the drug and how well it works.
Approximately 55 adult patients over age 18, both male and female will be enrolled. All patients will receive oral BGJ398, once daily, on a three weeks on (21 days), one week off (7 days) scheduleRead More
This study is a dose escalation study to determine the safety and tolerability of Ceramide NanoLiposome in patients with advanced solid tumors.Read More
This is an open-label (both the patient and the investigator know what the patient is receiving), Phase 2 study in patient with cholangiocarcinoma who have failed at least one prior line of therapy.Read More
An Open-label, Non-Randomized (the participants are not assigned by chance to different treatment groups), Multi-center, Phase I Study. Phase II Dose of the Orally taken Mutant IDH Inhibitor BAY 1436032. Cohorts will consist of patients representing the following IDH1-R132X-mutant intrahepatic cholangioncarcinoma, glioblastoma/ anaplastic gliomaRead More
This open-label study is looking at targeted therapies in patients with advanced cancer for whom there is no available, beneficial treatment.Read More